← Back to Screener
SANUWAVE Health, Inc. Common Stock (SNWV)
Price$15.85
Value ScoreC
Growth ScoreB
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-64.56%
Price vs S&P 500 (4W)-0.27%
VGM Score45.96
Market Capitalization$141.63M
P/E Ratio (Annual)11.99x
All Metrics
P/CF (Annual)36.54x
Book Value / Share (Quarterly)$0.21
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)38.05%
Cash Flow / Share (Quarterly)$0.45
Price vs S&P 500 (YTD)-55.74%
Gross Margin (TTM)76.74%
Net Profit Margin (TTM)36.21%
EPS (TTM)$1.77
10-Day Avg Trading Volume0.07M
EPS Excl Extra (TTM)$1.77
Revenue Growth (5Y)61.12%
EPS (Annual)$1.30
ROI (Annual)50.10%
Gross Margin (Annual)77.11%
Net Profit Margin (5Y Avg)-93.37%
Cash / Share (Quarterly)$1.25
P/E Basic Excl Extra (TTM)8.82x
Revenue Growth QoQ (YoY)2.97%
P/E Normalized (Annual)11.99x
ROA (Last FY)31.63%
Revenue Growth TTM (YoY)22.49%
EBITD / Share (TTM)$0.35
Operating Margin (TTM)4.88%
Cash Flow / Share (Annual)$0.23
P/B Ratio77.05x
P/B Ratio (Quarterly)80.85x
Net Income / Employee (Annual)$214,800
EV / Revenue (TTM)3.42x
Net Interest Coverage (TTM)0.30x
ROA (TTM)44.87%
EV / EBITDA (TTM)48.91x
EPS Incl Extra (Annual)$1.30
Current Ratio (Annual)1.38x
Quick Ratio (Quarterly)0.92x
3-Month Avg Trading Volume0.08M
52-Week Price Return-41.55%
EV / Free Cash Flow (Annual)78.29x
P/E Incl Extra (TTM)8.82x
Revenue / Employee (TTM)$806,000
Tangible BV / Share (Quarterly)$2.07
P/S Ratio (Annual)3.21x
Asset Turnover (Annual)1.18x
52-Week High$46.59
Operating Margin (5Y Avg)-33.61%
EPS Excl Extra (Annual)$1.30
CapEx CAGR (5Y)105.57%
26-Week Price Return-48.63%
Quick Ratio (Annual)0.97x
13-Week Price Return-34.33%
Total Debt / Equity (Annual)13.56x
Current Ratio (Quarterly)1.31x
Enterprise Value$151.42M
Revenue / Share Growth (5Y)3.84%
Asset Turnover (TTM)1.24x
Revenue / Employee (Annual)$800,900
Inventory Turnover (Annual)2.00x
Pretax Margin (Annual)27.01%
Cash / Share (Annual)$1.39
3-Month Return Std Dev69.82%
Gross Margin (5Y Avg)71.71%
Net Income / Employee (TTM)$291,800
ROE (Last FY)729.65%
Net Interest Coverage (Annual)0.73x
EPS Basic Excl Extra (Annual)$1.30
P/FCF (TTM)35.25x
Receivables Turnover (TTM)8.99x
EV / Free Cash Flow (TTM)39.31x
Total Debt / Equity (Quarterly)11.19x
EPS Incl Extra (TTM)$1.77
Receivables Turnover (Annual)10.07x
ROI (TTM)20.31%
P/S Ratio (TTM)3.19x
Pretax Margin (5Y Avg)-93.26%
Revenue / Share (Annual)$4.85
Tangible BV / Share (Annual)$-0.10
Forward P/E14.71x
Price vs S&P 500 (52W)-69.76%
P/E Ratio (TTM)8.82x
Year-to-Date Return-44.81%
5-Day Price Return-1.32%
EPS Normalized (Annual)$1.30
ROA (5Y Avg)-77.17%
Net Profit Margin (Annual)26.82%
Month-to-Date Return0.61%
Cash Flow / Share (TTM)$-0.08
EBITD / Share (Annual)$0.57
Operating Margin (Annual)9.70%
LT Debt / Equity (Annual)10.08x
P/CF (TTM)24.46x
P/E Excl Extra (TTM)8.82x
LT Debt / Equity (Quarterly)8.15x
EPS Basic Excl Extra (TTM)$1.77
P/TBV (Quarterly)88.90x
P/B Ratio (Annual)158.07x
Inventory Turnover (TTM)1.82x
Pretax Margin (TTM)36.40%
Book Value / Share (Annual)$0.19
Price vs S&P 500 (13W)-44.08%
Beta1.37x
P/FCF (Annual)73.23x
Revenue / Share (TTM)$5.16
ROE (TTM)270.18%
52-Week Low$15.36
vGradeC
gGradeB
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.18est. -0.05
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
4.13
4.13
4.13
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SNWVSANUWAVE Health, Inc. Common Stock | C | B | D | $15.85 |
| SYKStryker Corporation | C | C | D | $299.46 |
| MMM3M Company | C | F | C | $150.93 |
| BSXBoston Scientific Corp. | C | B | F | $47.98 |
| MDLNMedline Inc. Class A common stock | C | D | D | $35.75 |
| BDXBecton, Dickinson and Co. | B | C | C | $145.33 |
| DXCMDexCom, Inc. | C | B | C | $74.87 |
| RMDResMed Inc. | B | B | D | $186.44 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $316.30 |
| SOLVSolventum Corporation | C | D | C | $75.84 |
| PENPenumbra, Inc. | F | C | C | $318.95 |
About
SANUWAVE Health develops noninvasive ultrasound and shock wave technology for regenerative medicine, with a focus on wound healing. The company's two primary products, UltraMIST and PACE, are the only FDA-approved directed energy systems for this indication. This regulatory exclusivity provides a differentiated market position in the specialized wound care sector.